This is licensing only and does not include any costs for regulatory and clinical trial work. Initial license fee is $50,000 upfront plus a $10,000 minimum annual royalty for a total of $60,000. Phase 1 is an additional $100,000, Phase 2 is $250,000, Phase 3 $500,000, and BLA is $1,000,000. Each year an annual royalty payment of $10,000 will be due on the anniversay date of initial licensing. And finally there is a 6% royalty due on gross revenues from any succesful applications for use in the general population. This royalty will continue through the life of the patent(s) covering any particular disease.
To enter into clinical trials you may be required to conduct preclinical experiments before you author and file Investigational New Drug Applications (IND). We are available for consulting and assistance in authoring IND’s.
The following list of StemVacs™ cancer immunotherapy patents are available for licensing.
EX VIVO GENERATION OF IMMUNOCYTES RECOGNIZING BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS) EXPRESSING CANCER STEM CELLS
CHIMERIC CELLS COMPRISING DENDRITIC CELLS AND ENDOTHELIAL CELLS RESEMBLING TUMOR ENDOTHELIUM
STIMULATION OF DENDRITIC CELL ACTIVITY BY HOMOTAURINE AND ANALOGUES THEREOF
COMPOSITIONS CAPABLE OF STIMULATING IMMUNITY TOWARDS TUMOR BLOOD VESSELS
AUGMENTATION OF NATURAL KILLER CELL ACTIVITY AND INDUCTION OF CYTOTOXIC IMMUNITY USING LEUKOCYTE LYSATE ACTIVATED ALLOGENEIC DENDRITIC CELLS: STEMVACS
STIMULATION OF NATURAL KILL CELL MEMORY BY ADMINISTRATION OF DENDRITIC CELLS
IMMUNOTHERAPIES FOR TARGETING OF TUMOR VASCULATURE
PLURIPOTENT STEM CELL DERIVED DENDRITIC CELLS AND ENGINEERED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY